Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL ANTIBIOTIC RESISTANCE MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY BASED MODEL
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL ANTIBIOTIC RESISTANCE MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S 5 FORCES MODEL
6 EPIDEMIOLOGY
7 INDUSTRY INSIGHTS
8 THE EVOLVING RESPONSE TO ANTIBIOTIC RESISTANCE IN HOSPITALS
9 REGULATORY SCENARIO
10 PIPELINE ANALYSIS
10.1 PHASE III CANDIDATE
10.2 PHASE II CANDIDATE
10.3 PHASE I CANDIDATE
10.4 OTHERS
11 GLOBAL ANTIBIOTIC RESISTANCE MARKET, BY TYPE, 2022-2031, (USD MILLION)
11.1 OVERVIEW
11.2 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS
11.3 VANCOMYCIN-RESISTANT ENTEROCOCCI
11.4 DRUG-RESISTANT STREPTOCOCCUS PNEUMONIAE
11.5 DRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS
11.6 CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE)
11.7 MDR PSEUDOMONAS AERUGINOSA
11.8 MDR ACINETOBACTER
11.9 ESBL-PRODUCING ENTEROBACTERIACEAE
11.1 DRUG-RESISTANT NEISSERIA GONORRHOEAE
11.11 OTHERS
12 GLOBAL ANTIBIOTIC RESISTANCE MARKET, BY RESISTANCE TYPE, 2022-2031, (USD MILLION)
12.1 OVERVIEW
12.2 NATURAL RESISTANCE
12.2.1 INTRINSIC
12.2.2 INDUCED
12.3 ACQUIRED RESISTANCE
13 GLOBAL ANTIBIOTIC RESISTANCE MARKET, BY DRUGS, 2022-2031, (USD MILLION)
13.1 OVERVIEW
13.2 PRETOMANID
13.3 RECARBRIO
13.4 OMADACYCLINE
13.5 ARIKAYCE
13.6 ERAVACYCLIN
13.7 OZENOXACIN
13.8 DELAFLOXACIN
13.9 DAPTOMYCIN
13.1 DALBAVANCIN
13.11 OTHERS
14 GLOBAL ANTIBIOTIC RESISTANCE MARKET, BY RESISTANCE MECHANISMS, 2022-2031, (USD MILLION)
14.1 OVERVIEW
14.2 LIMITING UPTAKE OF A DRUG
14.3 MODIFYING A DRUG TARGET
14.4 INACTIVATING A DRUG
14.5 ACTIVE DRUG EFFLUX
15 GLOBAL ANTIBIOTIC RESISTANCE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031, (USD MILLION)
15.1 OVERVIEW
15.2 ORAL
15.3 PARENTERAL
15.4 TOPICAL
15.5 OTHERS
16 GLOBAL ANTIBIOTIC RESISTANCE MARKET, BY END USER, 2022-2031, (USD MILLION)
16.1 OVERVIEW
16.2 HOSPITALS
16.2.1 HOSPITALS, BY DRUGS
16.2.1.1. PRETOMANID
16.2.1.2. RECARBRIO
16.2.1.3. OMADACYCLINE
16.2.1.4. ARIKAYCE
16.2.1.5. ERAVACYCLIN
16.2.1.6. OZENOXACIN
16.2.1.7. DELAFLOXACIN
16.2.1.8. DAPTOMYCIN
16.2.1.9. DALBAVANCIN
16.2.1.10. OTHERS
16.3 SPECIALTY CLINICS
16.3.1 HOSPITALS, BY DRUGS
16.3.1.1. PRETOMANID
16.3.1.2. RECARBRIO
16.3.1.3. OMADACYCLINE
16.3.1.4. ARIKAYCE
16.3.1.5. ERAVACYCLIN
16.3.1.6. OZENOXACIN
16.3.1.7. DELAFLOXACIN
16.3.1.8. DAPTOMYCIN
16.3.1.9. DALBAVANCIN
16.3.1.10. OTHERS
16.4 HOME HEALTHCARE
16.4.1 HOSPITALS, BY DRUGS
16.4.1.1. PRETOMANID
16.4.1.2. RECARBRIO
16.4.1.3. OMADACYCLINE
16.4.1.4. ARIKAYCE
16.4.1.5. ERAVACYCLIN
16.4.1.6. OZENOXACIN
16.4.1.7. DELAFLOXACIN
16.4.1.8. DAPTOMYCIN
16.4.1.9. DALBAVANCIN
16.4.1.10. OTHERS
16.5 OTHERS
17 GLOBAL ANTIBIOTIC RESISTANCE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031, (USD MILLION)
17.1 OVERVIEW
17.2 DIRECT TENDER
17.3 RETAIL SALES
17.3.1 ONLINE STORES
17.3.2 PHARMACIES
17.3.3 OTHERS
17.4 OTHERS
18 GLOBAL ANTIBIOTIC RESISTANCE MARKET, COMPANY LANDSCAPE, 2022-2031, (USD MILLION)
18.1 COMPANY SHARE ANALYSIS: GLOBAL
18.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
18.3 COMPANY SHARE ANALYSIS: EUROPE
18.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
18.5 MERGERS & ACQUISITIONS
18.6 NEW PRODUCT DEVELOPMENT & APPROVALS
18.7 EXPANSIONS
18.8 REGULATORY CHANGES
18.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
19 GLOBAL ANTIBIOTIC RESISTANCE MARKET, BY GEOGRAPHY
GLOBAL ANTIBIOTIC RESISTANCE MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
19.1.1 NORTH AMERICA
19.1.1.1. U.S.
19.1.1.2. CANADA
19.1.1.3. MEXICO
19.1.2 EUROPE
19.1.2.1. GERMANY
19.1.2.2. FRANCE
19.1.2.3. U.K.
19.1.2.4. HUNGARY
19.1.2.5. LITHUANIA
19.1.2.6. AUSTRIA
19.1.2.7. IRELAND
19.1.2.8. NORWAY
19.1.2.9. POLAND
19.1.2.10. ITALY
19.1.2.11. SPAIN
19.1.2.12. RUSSIA
19.1.2.13. TURKEY
19.1.2.14. BELGIUM
19.1.2.15. NETHERLANDS
19.1.2.16. SWITZERLAND
19.1.2.17. REST OF EUROPE
19.1.3 ASIA-PACIFIC
19.1.3.1. JAPAN
19.1.3.2. CHINA
19.1.3.3. SOUTH KOREA
19.1.3.4. INDIA
19.1.3.5. AUSTRALIA
19.1.3.6. SINGAPORE
19.1.3.7. THAILAND
19.1.3.8. MALAYSIA
19.1.3.9. INDONESIA
19.1.3.10. PHILIPPINES
19.1.3.11. VIETNAM
19.1.3.12. REST OF ASIA-PACIFIC
19.1.4 SOUTH AMERICA
19.1.4.1. BRAZIL
19.1.4.2. ARGENTINA
19.1.4.3. PERU
19.1.4.4. REST OF SOUTH AMERICA
19.1.5 MIDDLE EAST AND AFRICA
19.1.5.1. SOUTH AFRICA
19.1.5.2. SAUDI ARABIA
19.1.5.3. UAE
19.1.5.4. EGYPT
19.1.5.5. KUWAIT
19.1.5.6. ISRAEL
19.1.5.7. REST OF MIDDLE EAST AND AFRICA
19.2 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
20 GLOBAL ANTIBIOTIC RESISTANCE MARKET, SWOT AND DBMR ANALYSIS
21 GLOBAL ANTIBIOTIC RESISTANCE MARKET, COMPANY PROFILE
21.1 PARATEK PHARMACEUTICALS, INC.( NOVO HOLDINGS A/S)
21.1.1 COMPANY OVERVIEW
21.1.2 REVENUE ANALYSIS
21.1.3 GEOGRAPHIC PRESENCE
21.1.4 PRODUCT PORTFOLIO
21.1.5 RECENT DEVELOPMENTS
21.2 MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC.
21.2.1 COMPANY OVERVIEW
21.2.2 REVENUE ANALYSIS
21.2.3 GEOGRAPHIC PRESENCE
21.2.4 PRODUCT PORTFOLIO
21.2.5 RECENT DEVELOPMENTS
21.3 INSMED INCORPORATED
21.3.1 COMPANY OVERVIEW
21.3.2 REVENUE ANALYSIS
21.3.3 GEOGRAPHIC PRESENCE
21.3.4 PRODUCT PORTFOLIO
21.3.5 RECENT DEVELOPMENTS
21.4 TETRAPHASE PHARMACEUTICALS, INC.
21.4.1 COMPANY OVERVIEW
21.4.2 REVENUE ANALYSIS
21.4.3 GEOGRAPHIC PRESENCE
21.4.4 PRODUCT PORTFOLIO
21.4.5 RECENT DEVELOPMENTS
21.5 MELINTA THERAPEUTICS, LLC
21.5.1 COMPANY OVERVIEW
21.5.2 REVENUE ANALYSIS
21.5.3 GEOGRAPHIC PRESENCE
21.5.4 PRODUCT PORTFOLIO
21.5.5 RECENT DEVELOPMENTS
21.6 THE TB ALLIANCE
21.6.1 COMPANY OVERVIEW
21.6.2 REVENUE ANALYSIS
21.6.3 GEOGRAPHIC PRESENCE
21.6.4 PRODUCT PORTFOLIO
21.6.5 RECENT DEVELOPMENTS
21.7 ABBVIE
21.7.1 COMPANY OVERVIEW
21.7.2 REVENUE ANALYSIS
21.7.3 GEOGRAPHIC PRESENCE
21.7.4 PRODUCT PORTFOLIO
21.7.5 RECENT DEVELOPMENTS
21.8 ACCORD HEALTHCARE
21.8.1 COMPANY OVERVIEW
21.8.2 REVENUE ANALYSIS
21.8.3 GEOGRAPHIC PRESENCE
21.8.4 PRODUCT PORTFOLIO
21.8.5 RECENT DEVELOPMENTS
21.9 MEITHEAL PHARMACEUTICALS
21.9.1 COMPANY OVERVIEW
21.9.2 REVENUE ANALYSIS
21.9.3 GEOGRAPHIC PRESENCE
21.9.4 PRODUCT PORTFOLIO
21.9.5 RECENT DEVELOPMENTS
21.1 TEVA PHARMACEUTICALS USA, INC.
21.10.1 COMPANY OVERVIEW
21.10.2 REVENUE ANALYSIS
21.10.3 GEOGRAPHIC PRESENCE
21.10.4 PRODUCT PORTFOLIO
21.10.5 RECENT DEVELOPMENTS
21.11 XELLIA PHARMACEUTICALS
21.11.1 COMPANY OVERVIEW
21.11.2 REVENUE ANALYSIS
21.11.3 GEOGRAPHIC PRESENCE
21.11.4 PRODUCT PORTFOLIO
21.11.5 RECENT DEVELOPMENTS
21.12 FRESENIUS KABI USA
21.12.1 COMPANY OVERVIEW
21.12.2 REVENUE ANALYSIS
21.12.3 GEOGRAPHIC PRESENCE
21.12.4 PRODUCT PORTFOLIO
21.12.5 RECENT DEVELOPMENTS
21.13 SAGENT PHARMACEUTICALS, INC.
21.13.1 COMPANY OVERVIEW
21.13.2 REVENUE ANALYSIS
21.13.3 GEOGRAPHIC PRESENCE
21.13.4 PRODUCT PORTFOLIO
21.13.5 RECENT DEVELOPMENTS
21.14 PFIZER INC.
21.14.1 COMPANY OVERVIEW
21.14.2 REVENUE ANALYSIS
21.14.3 GEOGRAPHIC PRESENCE
21.14.4 PRODUCT PORTFOLIO
21.14.5 RECENT DEVELOPMENTS
21.15 THERAVANCE BIOPHARMA
21.15.1 COMPANY OVERVIEW
21.15.2 REVENUE ANALYSIS
21.15.3 GEOGRAPHIC PRESENCE
21.15.4 PRODUCT PORTFOLIO
21.15.5 RECENT DEVELOPMENTS
21.16 CUMBERLAND PHARMACEUTICALS INC.
21.16.1 COMPANY OVERVIEW
21.16.2 REVENUE ANALYSIS
21.16.3 GEOGRAPHIC PRESENCE
21.16.4 PRODUCT PORTFOLIO
21.16.5 RECENT DEVELOPMENTS
21.17 ENDO PHARMACEUTICALS INC.
21.17.1 COMPANY OVERVIEW
21.17.2 REVENUE ANALYSIS
21.17.3 GEOGRAPHIC PRESENCE
21.17.4 PRODUCT PORTFOLIO
21.17.5 RECENT DEVELOPMENTS
21.18 CARB-X
21.18.1 COMPANY OVERVIEW
21.18.2 REVENUE ANALYSIS
21.18.3 GEOGRAPHIC PRESENCE
21.18.4 PRODUCT PORTFOLIO
21.18.5 RECENT DEVELOPMENTS
21.19 NOVITIUM PHARMA
21.19.1 COMPANY OVERVIEW
21.19.2 REVENUE ANALYSIS
21.19.3 GEOGRAPHIC PRESENCE
21.19.4 PRODUCT PORTFOLIO
21.19.5 RECENT DEVELOPMENTS
21.2 AXONICS INC.
21.20.1 COMPANY OVERVIEW
21.20.2 REVENUE ANALYSIS
21.20.3 GEOGRAPHIC PRESENCE
21.20.4 PRODUCT PORTFOLIO
21.20.5 RECENT DEVELOPMENTS
21.21 ENDOVENTURE
21.21.1 COMPANY OVERVIEW
21.21.2 REVENUE ANALYSIS
21.21.3 GEOGRAPHIC PRESENCE
21.21.4 PRODUCT PORTFOLIO
21.21.5 RECENT DEVELOPMENTS
21.22 VITACON
21.22.1 COMPANY OVERVIEW
21.22.2 REVENUE ANALYSIS
21.22.3 GEOGRAPHIC PRESENCE
21.22.4 PRODUCT PORTFOLIO
21.22.5 RECENT DEVELOPMENTS
21.23 BTL GROUP OF COMPANIES
21.23.1 COMPANY OVERVIEW
21.23.2 REVENUE ANALYSIS
21.23.3 GEOGRAPHIC PRESENCE
21.23.4 PRODUCT PORTFOLIO
21.23.5 RECENT DEVELOPMENTS
21.24 JUNE MEDICAL
21.24.1 COMPANY OVERVIEW
21.24.2 REVENUE ANALYSIS
21.24.3 GEOGRAPHIC PRESENCE
21.24.4 PRODUCT PORTFOLIO
21.24.5 RECENT DEVELOPMENTS
21.25 BOEHRINGER INGELHEIM GMBH
21.25.1 COMPANY OVERVIEW
21.25.2 REVENUE ANALYSIS
21.25.3 GEOGRAPHIC PRESENCE
21.25.4 PRODUCT PORTFOLIO
21.25.5 RECENT DEVELOPMENTS
21.26 CARBON MEDICAL TECHNOLOGIES, INC.
21.26.1 COMPANY OVERVIEW
21.26.2 REVENUE ANALYSIS
21.26.3 GEOGRAPHIC PRESENCE
21.26.4 PRODUCT PORTFOLIO
21.26.5 RECENT DEVELOPMENTS
21.27 MEDTRONIC
21.27.1 COMPANY OVERVIEW
21.27.2 REVENUE ANALYSIS
21.27.3 GEOGRAPHIC PRESENCE
21.27.4 PRODUCT PORTFOLIO
21.27.5 RECENT DEVELOPMENTS
21.28 BOSTON SCIENTIFIC CORPORATION
21.28.1 COMPANY OVERVIEW
21.28.2 REVENUE ANALYSIS
21.28.3 GEOGRAPHIC PRESENCE
21.28.4 PRODUCT PORTFOLIO
21.28.5 RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
22 RELATED REPORTS
23 CONCLUSION
24 QUESTIONNAIRE
25 ABOUT DATA BRIDGE MARKET RESEARCH
